Expert View on CAR T-Cell Therapy: Delving Into Evolving Topics, Critical Aspects of Management, and Practice-Changing Data

Review expert insights on incorporating CAR T-cell therapies into management of hematologic malignancies, including optimization of real-world patients, multidisciplinary management of toxicities, patient and caregiver education, and emerging data on the most promising investigational strategies.
Matthew J. Frigault, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 495 KB
Released: March 24, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Celgene Corporation
Gilead Sciences

Related Content

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v1.2020, from CCO

Released: October 16, 2020

Download this slideset to review the latest clinical data informing optimal management strategies for follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Download this ExpressPoints slideset for a quick summary of the latest clinical data informing optimal management of follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue